The RNA-Binding Proteins OAS1, ZFP36L2, and DHX58 Are Involved in the Regulation of CD44 MRNA Splicing in Colorectal Cancer Cells

Overview

Journal Bull Exp Biol Med

Publisher Springer

Specialty General Medicine

Date 2023 Jun 19

PMID 37336810

Authors

V O Novosad

D V Maltseva

Affiliations

Soon will be listed here.

Abstract

Regulation of alternative splicing is carried out by RNA-binding proteins. Each alternative splicing event is controlled by several RNA-binding proteins, which in combination create the distribution of alternative splicing products in a given cell type. Transmembrane protein CD44 plays an important role at various stages of the metastatic cascade and is considered as a promising molecule for the therapy of tumor diseases and the construction of prognostic classifiers. However, the functions of specific isoforms of this protein may differ significantly. In this work, we performed a bioinformatic search of RNA-binding proteins that can determine the expression of clinically significant isoforms 3 and 4 of CD44 protein. The analysis revealed five RNA-binding proteins, three of which (OAS1, ZFP36L2, and DHX58) are shown for the first time as potential regulators of the studied process.

Citing Articles

RNA-binding proteins regulating the CD44 alternative splicing.

Maltseva D, Tonevitsky A Front Mol Biosci. 2023; 10:1326148.

PMID: 38106992 PMC: 10722200. DOI: 10.3389/fmolb.2023.1326148.

References

Ponta H, Sherman L, Herrlich P . CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4(1):33-45. DOI: 10.1038/nrm1004. View

Wang Z, Zhao K, Hackert T, Zoller M . CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. Front Cell Dev Biol. 2018; 6:97. PMC: 6122270. DOI: 10.3389/fcell.2018.00097. View

Chen J, Zhou J, Lu J, Xiong H, Shi X, Gong L . Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer. 2014; 14:15. PMC: 3893437. DOI: 10.1186/1471-2407-14-15. View

Wang Z, Tang Y, Xie L, Huang A, Xue C, Gu Z . The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis. Front Oncol. 2019; 9:309. PMC: 6503057. DOI: 10.3389/fonc.2019.00309. View

Hong I, Hong S, Chang Y, Lee W, Lee B, Kang Y . Expression of the Cancer Stem Cell Markers CD44 and CD133 in Colorectal Cancer: An Immunohistochemical Staining Analysis. Ann Coloproctol. 2015; 31(3):84-91. PMC: 4496458. DOI: 10.3393/ac.2015.31.3.84. View

Azevedo R, Gaiteiro C, Peixoto A, Relvas-Santos M, Lima L, Santos L . CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications. Clin Proteomics. 2018; 15:22. PMC: 6020424. DOI: 10.1186/s12014-018-9198-9. View

Screaton G, Bell M, Jackson D, Cornelis F, Gerth U, Bell J . Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A. 1992; 89(24):12160-4. PMC: 50718. DOI: 10.1073/pnas.89.24.12160. View

Ruiz P, Schwarzler C, Gunthert U . CD44 isoforms during differentiation and development. Bioessays. 1995; 17(1):17-24. DOI: 10.1002/bies.950170106. View

Brown R, Reinke L, Damerow M, Perez D, Chodosh L, Yang J . CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121(3):1064-74. PMC: 3049398. DOI: 10.1172/JCI44540. View

10.

Zhang H, Brown R, Wei Y, Zhao P, Liu S, Liu X . CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 2019; 33(3-4):166-179. PMC: 6362815. DOI: 10.1101/gad.319889.118. View

11.

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

12.

Novosad V, Polikanova I, Tonevitsky E, Maltseva D . Expression of CD44 Isoforms in Tumor Samples and Cell Lines of Human Colorectal Cancer. Bull Exp Biol Med. 2022; 173(1):155-159. DOI: 10.1007/s10517-022-05512-4. View

13.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

14.

Ishii H, Saitoh M, Sakamoto K, Kondo T, Katoh R, Tanaka S . Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. J Biol Chem. 2014; 289(40):27386-99. PMC: 4183779. DOI: 10.1074/jbc.M114.589432. View

15.

Venables J, Brosseau J, Gadea G, Klinck R, Prinos P, Beaulieu J . RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol Cell Biol. 2012; 33(2):396-405. PMC: 3554129. DOI: 10.1128/MCB.01174-12. View

16.

Samatov T, Tonevitsky A, Schumacher U . Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer. 2013; 12(1):107. PMC: 3848796. DOI: 10.1186/1476-4598-12-107. View

17.

Senbanjo L, Chellaiah M . CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front Cell Dev Biol. 2017; 5:18. PMC: 5339222. DOI: 10.3389/fcell.2017.00018. View

18.

Lange T, Samatov T, Tonevitsky A, Schumacher U . Importance of altered glycoprotein-bound N- and O-glycans for epithelial-to-mesenchymal transition and adhesion of cancer cells. Carbohydr Res. 2014; 389:39-45. DOI: 10.1016/j.carres.2014.01.010. View

19.

Schwartz S, Park E, Vachon V, Danzy S, Lowen A, Conn G . Human OAS1 activation is highly dependent on both RNA sequence and context of activating RNA motifs. Nucleic Acids Res. 2020; 48(13):7520-7531. PMC: 7367156. DOI: 10.1093/nar/gkaa513. View

20.

Lohofener J, Steinke N, Kay-Fedorov P, Baruch P, Nikulin A, Tishchenko S . The Activation Mechanism of 2'-5'-Oligoadenylate Synthetase Gives New Insights Into OAS/cGAS Triggers of Innate Immunity. Structure. 2015; 23(5):851-862. DOI: 10.1016/j.str.2015.03.012. View